Financing type:  underwritten prospectus offering

Gross proceeds:  $6.86-million (U.S.)

Offering:  1,715,000 listed shares

Offering price:  $4 (U.S.) per listed share

Overallotment option:  The underwriters purchased a maximum of 223,695 listed shares for overallotment purposes. As of July 31, 2026, such option has been fully exercised. All information presented herein includes such exercise.

Public disclosure:  Refer to the prospectus supplement dated July 30, 2026, and the company's news releases dated July 30, 2026, and July 31, 2026.